Topical compositions and methods for epithelial-related conditions
View Patent ↗The present invention relates to pharmaceutical, cosmetic and cosmeceutical topical compositions containing polyisoprenyl-protein inhibitor compounds and methods useful in the promotion of healthy epithelium and the treatment of epithelial-related conditions.
1. A topical composition comprising:
N-acetyl-S-farnesylcysteine (“AFC”), also referred to as N-acetyl-S-trans, trans-farnesyl-L-cysteine, or a pharmaceutically acceptable salt thereof, present in the amount of about 0.1% to about 5% w/w; and
a carrier selected from the group consisting of water, ethanol, isopropanol, acetone, and combinations thereof, wherein the topical composition inhibits local inflammation when applied topically to the skin, without systemic anti-inflammatory effects.
2. The composition according to claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of an alkali metal salt, an alkaline earth metal salt, an ammonium salt and a substituted ammonium salt.
3. The composition according to claim 1 , further comprising an active ingredient other than AFC.
4. The composition according to claim 3 wherein the active ingredient is at least one ingredient selected from the group consisting of a protective agent, an emollient, an astringent, an irritant, a keratolytic agent, a sun screening agent, a sun tanning agent, an antibiotic agent, an antifungal agent, an antiviral agent, an antiprotozoal agent, an anti-acne agent, an anesthetic agent, a steroidal anti-inflammatory agent, a non-steroidal anti-inflammatory agent, an antipruritic agent, an anti-oxidant agent, an anti-histamine agent, a vitamin, a hormone, an anti-dandruff agent, an anti-wrinkle agent, an anti-skin atrophy agent, a sclerosing agent, a cleansing agent, a caustic agent and a hypo-pigmenting agent.
5. The composition according to claim 4 , wherein the protective agent is selected from the group consisting of an adsorbent, a demulcent and a desiccant.
6. The composition according to claim, 4 , wherein the irritant is a rubefacient.
7. The composition of claim 1 , further comprising a retinoid.
8. The composition of claim 7 , wherein said retinoid is at least one of vitamin A, retinol, retinal, retinyl palmitate, retinoic acid, tretinoin and iso-tretinoin.
9. The composition of claim 1 , further comprising an alpha-hydroxy acid.
10. The composition of claim 9 , wherein said alpha-hydroxy acid is at least one of glycolic acid, lactic acid, tartaric acid, malic acid or citric acid or a mixture thereof.
11. The composition of claim 1 , further comprising a beta-hydroxy acid.
12. The composition of claim 1 , further comprising an antibiotic agent.
13. The composition of claim 1 , further comprising an antifungal agent.
14. The composition of claim 1 , further comprising a sun screening agent.
15. The composition of claim 1 , further comprising a steroidal anti-inflammatory agent.
16. The composition of claim 1 , further comprising titanium oxide, zinc oxide, benzoyl peroxide, fluorouracil, resorcinol, or salicylic acid or a mixture thereof.
17. The topical composition of claim 1 , wherein the topical composition comprises hyaluronic acid.
18. The topical composition of claim 1 , wherein the topical composition comprises glycerin.
19. The topical composition of claim 1 , wherein the topical composition comprises at least one moisturizing agent.
20. The topical composition of claim 19 , wherein the moisturizing agent is selected from the group consisting of guanidines, glycolic acids, glycolate salts, aloe veras, allantoin, urazole, polyhydroxy alcohols, propylene glycol, butylene glycol, hexylene glycol, polyethylene glycols, sugars, starchs, alkoxylated glucose, hyaluronic acid, lactamide monoethanolamine, acetamide monoethanolamine, and combinations thereof.
21. The topical composition of claim 1 , wherein the topical composition has a pH between 4 and 7.
22. The topical composition of claim 20 , wherein the polyhydroxy alcohol is selected from the group consisting of sorbitol, glycerol, and hexanetriol.
23. The topical composition of claim 20 , wherein the glycolate salt is selected from the group consisting of ammonium salt and quarternary alkyl ammonium salt.
24. The topical composition of claim 1 , wherein the topical composition is in the form of a powder.
25. The topical composition of claim 1 , where in the topical composition is in the form of an oil.
26. The topical composition of claim 1 , wherein the topical composition is in the form of a cream.
27. The topical composition of claim 1 , wherein the topical composition is in the form of a gel.
28. The topical composition of claim 1 , wherein the topical composition is in the form of a solution.
29. The topical composition of claim 1 , wherein the topical composition is included in a bandage.
30. A topical composition comprising:
N-acetyl-S-farnesylcysteine (“AFC”), also referred to as N-acetyl-S-trans, trans-farnesyl-L-cysteine, or a pharmaceutically acceptable salt thereof, present in the amount of about 0.1% to about 5% w/w; and
a carrier selected from the group consisting of water, ethanol, isopropanol, acetone, and combinations thereof, wherein the topical composition inhibits local inflammation when applied topically, without systemic anti-inflammatory effects, so that local application of the composition to an isolated epithelial inflammation site on skin of a subject reduces inflammation at that site, but not at a distal site of inflammation.